Medicinal Products

2136. Deputy Colm Burke asked the Minister for Health if she will confirm that a product (details supplied) will be placed under the Health Service Executive reimbursable items list so that persons under this scheme can avail of a 2.4mg maximum dosage compared to another product (details supplied) where the maximum dose is 1mg and is only reimbursed for the treatment of diabetes; and if she will m…

2142. Deputy Conor Sheehan asked the Minister for Health if she is aware of difficulties that have arisen with transgender women accessing the free HRT scheme; and if she will make a statement on the matter. [44850/25]

2184. Deputy Ciarán Ahern asked the Minister for Health to address the misunderstanding around the free HRT scheme, whereby eligibility has erroneously been assessed on the basis of the purpose of the prescribed menopause product by participating pharmacies rather than on the basis of being prescribed menopause products, as per section 3 of S.I. No. 226/2025 – Health Act 1970 (Section 59(4)) (Meno…

2232. Deputy Liam Quaide asked the Minister for Health the eligibility of transgender women under the free hormone replacement therapy scheme; and if she will make a statement on the matter. [45221/25]

2241. Deputy Roderic O'Gorman asked the Minister for Health if the free hormone replacement therapy scheme for those experiencing menopause symptoms includes non-cisgendered women experiencing those symptoms; if not, the reason and by which method is it proposed to provide access to the same products on the same basis; and if she will make a statement on the matter. [45258/25]

2317. Deputy Denise Mitchell asked the Minister for Health the status of the health technology assessment of the muscular dystrophy drug (details supplied); if she will consider the inclusion of this drug on the drugs payment scheme; and if she will make a statement on the matter. [45581/25]

2337. Deputy Barry Ward asked the Minister for Health the position regarding the eligibility of transgender women under the free hormone replacement therapy scheme; if this matter has been clarified with the Irish Pharmacy Union; and if she will make a statement on the matter. [45631/25]

2345. Deputy Cian O'Callaghan asked the Minister for Health if she will provide an update on the processing of a medication (details supplied) on the HSE reimbursement list; and if she will make a statement on the matter. [45641/25]

2347. Deputy Seán Fleming asked the Minister for Health when a medication (details supplied) to treat people who have a nut allergy will be made available for those under 18 years of age; and if she will make a statement on the matter. [45650/25]

2414. Deputy Ruth Coppinger asked the Minister for Health the eligibility of people accessing HRT for gender affirming care under the free HRT scheme; and if she will make a statement on the matter. [45876/25]

2430. Deputy Jen Cummins asked the Minister for Health to clarify if under the free HRT scheme transgender people who require HRT can also avail of it for free when prescribed by a doctor; and if she will make a statement on the matter. [46028/25]

2446. Deputy Sorca Clarke asked the Minister for Health her views on the continued use of pharmaceutical products manufactured by Israeli companies within the HSE, in light of calls from CHI consultants to end the use of Israeli drugs; and if she will make a statement on the matter. [46140/25]

2618. Deputy Cormac Devlin asked the Minister for Health if she will provide an update on the NCPE appraisal of ritlecitinib (litfulo) for severe alopecia areata, including current stage, any ongoing HSE pricing and reimbursement engagement with the applicant; the expected timelines for a decision and proposed prescribing setting if approved; and if she will make a statement on the matter. [46999/…

2619. Deputy Cormac Devlin asked the Minister for Health if an application has been received by the HSE for pricing and reimbursement of baricitinib for the alopecia areata indication; if not, if the HSE or her Department has engaged with the marketing authorisation holder regarding a submission; and if she will make a statement on the matter. [47000/25]

2620. Deputy Cormac Devlin asked the Minister for Health if her Department, the HSE or the HPRA has engaged with the manufacturer of deuruxolitinib (leqselvi) regarding plans for EU submission and availability in Ireland; if any named-patient or compassionate access requests have been received; and if she will make a statement on the matter. [47001/25]

2646. Deputy Cormac Devlin asked the Minister for Health the current days of cover for the top 100 essential medicines, by category; the medicines experiencing repeated shortages since 2023; the plan to establish a rotating national reserve and domestic fill finish capacity; and if she will make a statement on the matter. [47208/25]

2551. Deputy Darren O'Rourke asked the Minister for Health for an update on the assessment, funding and use, including early use through an early access scheme, of givinostat for muscular dystrophy patients; and if she will make a statement on the matter. [40811/25]

2573. Deputy Paula Butterly asked the Minister for Health to respond to correspondence (details supplied) regarding treatments for adults living with spinal muscular atrophy in Ireland; and if she will make a statement on the matter. [40959/25]

2575. Deputy Aengus Ó Snodaigh asked the Minister for Health the steps being taken to address the growing concern re the shortage of salbutamol. [40971/25]

2584. Deputy Barry Ward asked the Minister for Health further to Parliamentary Question No. 904 of 15 July 2025, if she will engage with a union (details supplied) to encourage the use of European-made medications wherever possible; and if she will make a statement on the matter. [40998/25]

2602. Deputy David Cullinane asked the Minister for Health if she has engaged with her counterpart in the North to explore the potential for maximising access to new medicines while ensuring value for money through joint arrangements, such as for gavinostat for which there is a pricing arrangement in the North, but not in this State, but a lack of capacity to issue the treatment; and if she will m…

2649. Deputy Barry Heneghan asked the Minister for Health the plans in place for the assessment and potential inclusion of the psychiatric medication lumateperone for the treatment of bipolar disorder under the drug payment scheme; and if she will make a statement on the matter. [41240/25]

2678. Deputy Ciarán Ahern asked the Minister for Health if she is aware of the growing use of HHC (hexahydrocannabinol) vapes, a synthetic cannabinoid product, among young people; if the new Public Health (Nicotine Inhaling Products) Bill 2025 will contain provisions to curtail this trend; and if not, if she will produce separate legislation on the matter; and if she will make a statement on the m…

2679. Deputy Pádraig Rice asked the Minister for Health if the Medicines Management Programme’s proposed reclassification of high protein (HP) oral nutrition supplements to list B will be suspended to allow the scientific data to be properly evaluated; if she is aware of thejoint position statement detailing the clinical, ethical, and economic concerns associated with this proposal endorsed by ove…

2680. Deputy Pádraig Rice asked the Minister for Health if she will request that the Medicines Management Programme begins formal engagement with the Irish Society for Clinical Nutrition and Metabolism, the Irish Nutrition and Dietetic Institute and academic nutrition leaders to revise guidance on high-protein (HP) ONS products in line with international expert consensus; and if she will make a st…